Navigation Links
Epizyme, Inc. Granted Notice of Allowance of Patent for EPZ-5676

CAMBRIDGE, Mass., Sept. 3, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 13/310,157 "SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS" with claims covering the novel compound EPZ-5676. Epizyme's EPZ-5676 is a small molecule DOT1L inhibitor designed to treat acute leukemias in which the MLL gene is rearranged due to a chromosomal translocation (MLL-r).

About EPZ-5676

Epizyme is developing EPZ-5676, a small molecule inhibitor of DOT1L created with Epizyme's proprietary product platform, for the treatment of acute leukemias in which the MLL gene is rearranged due to a chromosomal translocation (MLL-r). Due to the translocation, DOT1L is recruited to specific locations in the chromosome where it would not normally be present. As a result, DOT1L causes inappropriate methylation at these locations, which results in the increased expression of genes causing leukemia.

In September 2012, Epizyme initiated a Phase 1 clinical trial for EPZ-5676. The company believes EPZ-5676 is the first HMTi to enter human clinical development. As of August 2013, this program is in the dose escalation phase and is expected to initiate an expansion phase in the second half of 2013 that will exclusively enroll MLL-r patients.

Epizyme retains all U.S. rights to EPZ-5676 and has granted Celgene an exclusive license to EPZ-5676 outside of the United States. Epizyme has partnered with Abbott to develop a companion diagnostic to identify MLL-r patients. Additional information about these partnerships may be found here:

About MLL-r

MLL-r is an aggressive subtype of two of the most common forms of acute leukemia, acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL). The disease predominantly occurs in two different age ranges, an adult population and a pediatric population. Although both age ranges share a common genetic driver, the adult disease is frequently a secondary leukemia resulting from prior chemotherapy for a different, unrelated cancer, while the pediatric disease is sporadic in nature. According to research published in the journal Blood in December 2002, the five-year overall survival rate for adult patients with the MLL-r subtype of AML ranges from approximately 5 to 24 percent. The five-year event-free survival rate in pediatric patients with the most common MLL-r subtype of ALL is approximately 27 percent, as identified in research published in the New England Journal of Medicine in 2004. The total annual incidence of MLL-r in all patients (adult and pediatric, AML and ALL) in major pharmaceutical markets is approximately 4,900 patients, according to a report by Clarion Healthcare commissioned by Epizyme. Patients with MLL-r are routinely diagnosed today with existing tests that are commonly used in clinical settings, and there is high awareness of MLL-r among oncologists.

About Epizyme, Inc.

Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Epizyme, Inc. to Present at Upcoming Conferences in September
2. Epizyme, Inc. to Present at Wedbush Securities Life Sciences Management Access Conference in August
3. Epizyme, Inc. to Webcast Conference Call Discussing Second Quarter 2013 Financial Results on July 31, 2013
4. Epizyme, Inc. Announces Pricing of Initial Public Offering
5. Epizyme, Inc. Files Registration Statement for Proposed Initial Public Offering
6. Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
7. Trevena Granted Key Composition of Matter Patent for TRV027 in U.S.
8. CorMedix Granted Extension of NYSE MKT Listing
9. QRxPharma Granted US Patent On Hybrid Opioids
10. Mapi Pharma Granted United States Patent Covering Glatiramer Depot for Multiple Sclerosis
11. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
Breaking Medicine Technology:
(Date:11/26/2015)... Bangalore, Karnataka (PRWEB) , ... ... ... an innovative online platform for mental health and wellness consultation, has collaborated ... self-empowerment, to holistically address their reader’s queries on topics on mental and ...
(Date:11/25/2015)... Indianapolis, IN (PRWEB) , ... November 25, 2015 ... ... clean water accessible for all, Water For Empowerment ™ attracts volunteers together ... on clean water by empowering women as key stakeholders in the process. The ...
(Date:11/25/2015)... Neb. (PRWEB) , ... November 25, 2015 , ... ... staffing companies, has been recognized once again for its stellar workplace culture with ... to Work.” , Medical Solutions’ Cincinnati office was named a finalist ...
(Date:11/25/2015)... ... , ... Ministers, senior government and UN agencies, representatives from ... Excellence, and public R&D institutions, civil societies and other partners gathered today at ... Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day meeting ...
(Date:11/25/2015)... Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... da Vinci surgical robot is being more and more widely heralded as a breakthrough ... assisted da Vinci method has over traditional laparoscopic surgery is that it can greatly ...
Breaking Medicine News(10 mins):